Kobo Biotech

Why is Kobo Biotech Ltd falling/rising?

As of 04-Aug, Kobo Biotech Ltd's stock price is currently at 7.69, reflecting a decline of 4.94% and significant underperformance over the past week and month. Despite impressive year-to-date growth of 221.76%, recent trends indicate short-term weakness and underperformance against its sector and benchmark.

As of 04-Aug, Kobo Biotech Ltd's stock price is falling, currently at 7.69, which reflects a decrease of 0.4 or 4.94%. This decline is evident in the stock's performance over the past week, where it has underperformed significantly, showing a drop of 10.16% compared to a 2.17% increase in the Sensex. Additionally, the stock has experienced a negative trend over the past month, with a decrease of 7.13%, while the benchmark index has gained 0.86%.<BR><BR>Despite the current drop, it is noteworthy that Kobo Biotech Ltd has shown impressive year-to-date growth of 221.76%, significantly outperforming the Sensex, which has declined by 7.97% in the same period. However, the stock's performance today indicates it has underperformed its sector by 4.88%. <BR><BR>The moving averages indicate that while the stock is above the 50-day, 100-day, and 200-day moving averages, it is below the 5-day and 20-day moving averages, suggesting a short-term weakness. Furthermore, there has been a notable increase in investor participation, with a delivery volume of 2.95 lacs on 03 Aug, which has risen by 681.75% against the 5-day average, indicating some interest despite the price decline. <BR><BR>In summary, the combination of recent underperformance against both the sector and the benchmark, along with the current price drop, contributes to the overall falling trend of Kobo Biotech Ltd's stock price.

Which are the latest news on Kobo Biotech?

How big is Kobo Biotech?

As of 10th June, Kobo Biotech Ltd has a market capitalization of 14.00 Cr, with reported Net Sales of 0.00 Cr and a loss of 5.04 Cr in Net Profit over the latest four quarters. The latest balance sheet shows Shareholder's Funds of 53.08 Cr and Total Assets of 395.58 Cr.

As of 10th June, Kobo Biotech Ltd has a market capitalization of 14.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kobo Biotech reported Net Sales of 0.00 Cr and a loss of 5.04 Cr in Net Profit.<BR><BR>The latest annual period for the balance sheet is March 2015, with Shareholder's Funds amounting to 53.08 Cr and Total Assets of 395.58 Cr.

Who are in the management team of Kobo Biotech?

The management team of Kobo Biotech includes Ajit Kamath (Chairman), Rajendra Kaimal (Non-Executive Director), Jignesh Patel (Company Secretary), and independent directors Sunil Pitroda, Abhishek Buddhadev, and Urja Shah.

The management team of Kobo Biotech includes the following individuals:<BR><BR>1. Ajit Kamath - Chairman (Non-Executive)<BR>2. Rajendra Kaimal - Non-Executive & Non-Independent Director<BR>3. Jignesh Patel - Company Secretary & Compliance Officer<BR>4. Sunil Pitroda - Non-Executive & Independent Director<BR>5. Abhishek Buddhadev - Non-Executive & Independent Director<BR>6. Urja Shah - Non-Executive & Independent Director<BR><BR>If you have any more questions about the company or its management, feel free to ask!

Who are the peers of the Kobo Biotech?

Kobo Biotech's peers include Square Four Pro., Jayshree Chem., Vivid Global, and others, with varying management risks and growth rates. Vivid Global has the highest 1-year return at 21.17%, while Kobo Biotech leads significantly with 134.11%.

Peers: The peers of Kobo Biotech are Square Four Pro., Jayshree Chem., Vivid Global, Sreechem Resins, Emmessar Biotech, Kuwer Industries, Link Pharma Chem, Lime Chemicals, Bhagawati Oxygen, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sreechem Resins, while Average management risk is found at Emmessar Biotech and the rest. Below Average management risk is noted at Square Four Pro., Jayshree Chem., Vivid Global, Kuwer Industries, Link Pharma Chem, Lime Chemicals, and Padmanabh Inds., while the rest do not qualify. Growth is Average at Jayshree Chem. and Padmanabh Inds., while Below Average growth is seen at Vivid Global, Sreechem Resins, Emmessar Biotech, Kuwer Industries, Link Pharma Chem, Lime Chemicals, and the rest. The Capital Structure is Good at Vivid Global, while Below Average is noted at Jayshree Chem., Emmessar Biotech, Kuwer Industries, Link Pharma Chem., Lime Chemicals, and the rest, with Square Four Pro., Kobo Biotech, and Bhagawati Oxygen not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vivid Global at 21.17%, while the lowest is Bhagawati Oxygen at -37.07%. Kobo Biotech's 1-year return is 134.11%, significantly higher than both. Additionally, Emmessar Biotech, Link Pharma Chem, Lime Chemicals, and Bhagawati Oxygen have negative six-month returns.

What does Kobo Biotech do?

Kobo Biotech Ltd is a manufacturer of active pharmaceutical ingredients (API) in the commodity chemicals sector, established in 1992 and rebranded in 2020. As of June 2024, it has a market cap of INR 14 Cr and reported a net profit of -1 Cr.

Overview:<BR>Kobo Biotech Ltd is a customer-centric manufacturer of active pharmaceutical ingredients (API) operating in the commodity chemicals industry within the micro cap market.<BR><BR>History:<BR>Kobo Biotech Ltd was established as a Public Limited Company on August 3, 1992, and changed its name from Avon Lifesciences Ltd to Kobo Biotech Limited on October 19, 2020. The latest quarterly results reported are for June 2024.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2024)<BR>Market-cap value: INR 14 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 42<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.05<BR>Return on Equity: 3.71%<BR>Price to Book: -0.10<BR><BR>Contact Details:<BR>Address: Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills Hyderabad Telangana : 500034<BR>Email: info@avonlifesciences.com

Should I buy, sell or hold Kobo Biotech Ltd?

Is Kobo Biotech overvalued or undervalued?

As of April 25, 2023, Kobo Biotech is considered overvalued and risky due to its negative financial metrics, including a PE ratio of -1.30 and a one-year stock return of -43.42%, significantly underperforming compared to healthier peers like Godrej Industries.

As of 25 April 2023, Kobo Biotech's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, primarily due to its negative PE ratio of -1.30, an EV to EBITDA ratio of -145.92, and a ROCE of -74.85%. These ratios highlight severe profitability issues and suggest that the company is struggling to generate positive returns.<BR><BR>In comparison to its peers, Kobo Biotech's financial metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a much healthier valuation. Other peers like Solar Industries are considered very expensive with a PE ratio of 123.77. Additionally, Kobo Biotech's recent stock performance has been poor, with a one-year return of -43.42%, significantly underperforming the Sensex's 7.61% return over the same period. This further reinforces the notion that the company is overvalued in its current state.

What is the technical trend for Kobo Biotech?

As of May 26, 2025, Kobo Biotech's technical trend has shifted to bearish, supported by negative MACD, Bollinger Bands, and moving averages across multiple time frames, along with poor performance against the Sensex.

As of 26 May 2025, the technical trend for Kobo Biotech has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish trend in both time frames. Daily moving averages confirm the bearish sentiment. The KST is bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish stance on the weekly and monthly levels. Overall, the strength of the bearish trend is reinforced by the negative performance against the Sensex, particularly over the past year and three years.

Are Kobo Biotech latest results good or bad?

Kobo Biotech's latest results for Q1 2024 are disappointing, showing a decline in financial health with an operating profit of Rs -0.34 crore and a profit before tax of Rs -1.35 crore, leading to a 'Sell' recommendation from MarketsMOJO. Investors should be cautious due to these negative trends.

Kobo Biotech's latest financial results for the quarter ending March 2024 indicate a challenging period for the company. The performance has been flat, with a score of -3, reflecting a decline in financial health compared to the previous quarter. <BR><BR>The operating profit (PBDIT) was recorded at Rs -0.34 crore, marking the lowest point in the last five quarters, which suggests a negative trend in operational performance. Similarly, the profit before tax (PBT) also hit its lowest at Rs -1.35 crore, indicating ongoing struggles with profitability.<BR><BR>Earnings per share (EPS) fell to Rs -0.56, again the lowest in recent quarters, which is not favorable for shareholders. Overall, the results have fallen below expectations, and the 'Sell' call from MarketsMOJO further emphasizes the negative outlook for the company. Investors should be cautious and consider these trends before making any investment decisions.

How has been the historical performance of the Kobo Biotech?

Kobo Biotech experienced significant financial decline from March 2013 to March 2014, with net sales dropping from Rs 403.66 crore to Rs 103.19 crore, resulting in a loss of Rs 34.82 crore after tax and a negative earnings per share of Rs -15.47. Overall, the year was marked by decreasing revenues and increasing losses.

Answer:<BR>The historical performance of Kobo Biotech shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Kobo Biotech's net sales have seen a decline from Rs 403.66 crore in March 2013 to Rs 103.19 crore in March 2014. This drop is mirrored in total operating income, which also fell from Rs 403.66 crore to Rs 103.19 crore in the same period. The company's total expenditure, excluding depreciation, decreased from Rs 360.78 crore in March 2013 to Rs 108.80 crore in March 2014, leading to an operating profit (PBDIT) that shifted from a profit of Rs 43.24 crore to a loss of Rs 0.68 crore. Consequently, the profit before tax turned negative, dropping from Rs 14.87 crore in March 2013 to Rs -34.27 crore in March 2014, resulting in a profit after tax of Rs -34.82 crore. The earnings per share (EPS) reflected this downturn, falling from Rs 6.07 to Rs -15.47. On the balance sheet, total liabilities remained stable at Rs 411.68 crore, while total assets also held steady at Rs 411.68 crore. Cash flow from operating activities decreased significantly, from Rs 36.72 crore in March 2013 to Rs 6.72 crore in March 2014, contributing to a net cash outflow of Rs -10.84 crore. Overall, Kobo Biotech's financial performance in March 2014 indicates a challenging year marked by declining revenues and increasing losses.

Who are the top shareholders of the Kobo Biotech?

The top shareholders of Kobo Biotech are Arch Pharmalabs Ltd with 44.95%, and individual investors who own 48.27%. The largest public shareholder is Mehul Pravin Chandra Shah at 1.1%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Kobo Biotech include Arch Pharmalabs Ltd, which holds the largest share at 44.95%. Additionally, individual investors collectively own 48.27% of the company. The highest public shareholder is Mehul Pravin Chandra Shah, who holds 1.1%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

When is the next results date for Kobo Biotech?

No Upcoming Board Meetings

Has Kobo Biotech declared dividend?

Kobo Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 21, 2012. However, the company has shown significant fluctuations in total returns, with negative returns in shorter periods and a positive return only over the 5-year period.

Kobo Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Sep-21-2012<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.16%, the dividend return was 0%, resulting in a total return of -17.16%.<BR><BR>In the 1-year period, the price return was -42.43%, the dividend return was 0%, resulting in a total return of -42.43%.<BR><BR>In the 2-year period, the price return was 3.72%, the dividend return was 0%, resulting in a total return of 3.72%.<BR><BR>In the 3-year period, the price return was -52.64%, the dividend return was 0%, resulting in a total return of -52.64%.<BR><BR>In the 4-year period, the price return was -58.1%, the dividend return was 0%, resulting in a total return of -58.1%.<BR><BR>In the 5-year period, the price return was 28.72%, the dividend return was 0%, resulting in a total return of 28.72%.<BR><BR>Overall, Kobo Biotech has declared a dividend, but the total returns over various periods show significant fluctuations, with negative returns dominating in the shorter time frames and a positive return only in the 5-year period. The lack of a current dividend yield indicates that recent performance may not be favorable for investors seeking income from dividends.